Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study

[1]  E. Crespan,et al.  Synthesis and biological activity evaluation of 3-(hetero) arylideneindolin-2-ones as potential c-Src inhibitors , 2022, Journal of enzyme inhibition and medicinal chemistry.

[2]  A. Vecchione,et al.  CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review , 2022, Frontiers in Oncology.

[3]  A. Vecchione,et al.  p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer , 2021, Cell Death & Disease.

[4]  Wei Zheng,et al.  Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva , 2020, bioRxiv.

[5]  A. Angelucci,et al.  Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far , 2020, Cancers.

[6]  J. O’Shaughnessy,et al.  Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients , 2019, npj Breast Cancer.

[7]  M. Bennett,et al.  An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain , 2019, Journal of bone oncology.

[8]  D. Spicer,et al.  Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer , 2018, Journal of Hematology & Oncology.

[9]  W. Gradishar,et al.  Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer. , 2017, The oncologist.

[10]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[11]  John C. Dawson,et al.  Rapid Discovery and Structure–Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase , 2016, Journal of medicinal chemistry.

[12]  I. Holen,et al.  Effects of Src-kinase inhibition in cancer-induced bone pain , 2016, Molecular pain.

[13]  S. Loi,et al.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. , 2016, The Lancet. Oncology.

[14]  P. Neven,et al.  Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Y. Qi,et al.  Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer , 2014, Clinical Cancer Research.

[16]  Kathleen A Cronin,et al.  US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. , 2014, Journal of the National Cancer Institute.

[17]  P. Neven,et al.  Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. , 2014, The oncologist.

[18]  J. Watanabe,et al.  First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours , 2013, Investigational New Drugs.

[19]  M. Soellner,et al.  Development of a highly selective c-Src kinase inhibitor. , 2012, ACS chemical biology.

[20]  S. Aamdal,et al.  Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours , 2012, British Journal of Cancer.

[21]  J. Baselga,et al.  Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study. , 2012, Bone.

[22]  R. Epstein,et al.  Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  G. Curigliano,et al.  PD01-02: Randomized Phase II Study of Dasatinib vs Placebo in Addition to Exemestane in Advanced ER/PR-Positive Breast Cancer [BMS CA180-261 Study]. , 2011 .

[24]  J. O’Shaughnessy,et al.  PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor. , 2011 .

[25]  Chau Dang,et al.  Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. , 2011, Clinical breast cancer.

[26]  K. Blackwell,et al.  Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing , 2011, Clinical Cancer Research.

[27]  P. Clézardin.  Therapeutic targets for bone metastases in breast cancer , 2011, Breast Cancer Research.

[28]  Zhenlin Ju,et al.  Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo , 2011, Breast Cancer Research and Treatment.

[29]  J. Baselga,et al.  Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors , 2010, Clinical Cancer Research.

[30]  Richard Eastell,et al.  Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose phase I trial , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  E. Mallon,et al.  Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients? , 2009, The American journal of pathology.

[32]  Ian Collins,et al.  Measuring and interpreting the selectivity of protein kinase inhibitors , 2009, Journal of chemical biology.

[33]  R. Nicholson,et al.  Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells , 2009, Breast Cancer Research and Treatment.

[34]  R. Finn,et al.  Targeting Src in breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  Yanping Wang,et al.  A three‐outcome design for randomized comparative phase II clinical trials , 2007, Statistics in medicine.

[36]  L. Hengst,et al.  p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2 , 2007, Cell.

[37]  Richard W. Kriwacki,et al.  Cdk-Inhibitory Activity and Stability of p27 Kip1 Are Directly Regulated by Oncogenic Tyrosine Kinases , 2007, Cell.

[38]  S. Fuqua,et al.  Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor–positive human breast cancer cells , 2006, Molecular Cancer Therapeutics.

[39]  R. Eastell,et al.  The effect of AZD0530, a highly selective, orally available Src/Abl kinase inhibitor, on biomarkers of bone resorption in healthy males , 2005 .

[40]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.